Drug tie-up boosts biotech group
Wednesday 01 April 1998
Shares in Chiroscience, the biotechnology group, soared 60p to 323.5p - a 23 per cent surge - as it unveiled one of Europe's biggest ever drug tie-ups. In marked contrast Smith & Nephew, the UK's largest healthcare group, admitted the development of Dermagraft, its skin grafting treatment which uses human tissue from the foreskin of circumcised babies, had met with problems in the US which sent its shares tumbling 12p to 166p.
Chiroscience expects to receive at least pounds 200m in payments and royalties from Zeneca, the pharmaceutical giant, for developing Chirocaine, a local anaesthetic. Zeneca is also buying pounds 15m worth of new Chiroscience shares, giving it a holding of just over 3 per cent in the biotech group.
Chirocaine lasts much longer than other local anaesthetics currently on the market, and can be used to numb areas of the body for up to 48 hours at a time. Patients will soon be able to undergo operations such as hip replacements using the new treatment rather than having to be rendered unconscious by a general anaesthetic. Chiroscience believes this will save the medical industry many millions of pounds by reducing the time patients will have to stay in hospital.
Dr John Padfield, chief executive of Chiroscience, said that the market for such local anaesthetics was growing rapidly and predicted that Chirocaine was likely to have peak sales of pounds 250m a year. "We will get a minimum of pounds 200m from Zeneca but that looks like a conservative figure," he added.
Chiroscience also plans to explore ways of using Chirocaine to help reduce pain for patients after they have undergone serious operations. Chirocaine is due to be launched in Europe during 1998 and in the US next year.
Meanwhile Smith & Nephew has been forced to recall some of its Dermagraft products after a routine visit by the Federal Drugs Administration to manufacturing facilities in the US unearthed production problems. The American launch of Dermagraft is now likely to be delayed for several months.
S&N admitted that Advanced Tissue Sciences, its US partner, had of not followed the right production procedures, including not documenting research or monitoring results properly.
Chris O'Donnell, the group's chief executive, admitted the findings added to the uncertainty surrounding Dermagraft but said it should not seriously damage chances of the treatment being launched in the US market later this year. "This is an annoying setback rather than a major heartache," he said. S&N has now sent three of its own employees over to sort out the problems.
S&N is the first company in the world to develop the bio-engineered skin which helps cure foot ulcers in diabetics and could eventually be used for cartilage and ligament injuries.
New UK station Russia Today gives a very bizarre view of Britain
Top Gear presenter is no stranger to foot-in-mouth controversy
New essay by JK Rowling went live on Pottermore site this morning
Charlie Sheen could be set to revive his role as a hedonistic womaniser
Review: Alexandre Aja's film is a Twin Peaks-style mystery
Review: Mike Leigh's biopic is a rambling, rich character study
- 1 'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
- 2 Canadian actor punched in face after 'Islamophobia' experiment goes wrong in wake of Ottawa shooting
- 3 Topshop at centre of row over body image as 'shocking' skinny mannequin photo goes viral
- 4 If you think Russell Brand’s new book is confused, you should read what his critics have to say about it
- 5 Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
'Nasa Confirms Six Days of Darkness in December': No, they don't - it's a hoax
Canadian actor punched in face after 'Islamophobia' experiment goes wrong in wake of Ottawa shooting
Halloween 2014: From the Screaming Man of Pluckley to the 'White Lady' of the Tower of London - Britain's 20 most haunted places
Russian politician says Apple CEO Tim Cook should be 'banned' from country after coming out as gay
Kentucky gang rape: 15-year-old boy left in critical condition after sexual attack by group at party
Pope Francis declares evolution and Big Bang theory are real and God is not 'a magician with a magic wand'
Huge surge in Ukip support after EU funding row, according to new poll
Ukip ‘exploiting grooming scandal’ to secure party’s first police chief
Nigel Farage: 'There’s nothing wrong with white people blacking up'
Maureen Lipman says 'she can't vote Labour while Ed Miliband is leader'
Muslims, immigration and teenage pregnancy: British people are ignorant about almost everything
iJobs Money & Business
£18000 - £23000 per annum + Comission: SThree: SThree, International Recruitme...
£20000 - £25000 per annum + OTE £35K: SThree: We consistently strive to be the...
£20000 - £23250 Per Annum pro rata: Clearwater People Solutions Ltd: Pro rata ...
£40 - 48k + Benefits: Guru Careers: We are seeking a Marketing Manager to join...